Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Dieter Zopf(Bayer (Germany)), Michael Gerisch(Bayer (Germany))
Cited by 100
Related Papers
Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
|International Journal of Cancer|2013|137